Title |
Author |
Type |
Words |
2seventy Bio reports Q1 EPS ($3.20), consensus ($2.05). |
|
Financial report |
155 |
4D Molecular reports Q1 EPS (82c), consensus (81c). |
|
Financial report |
166 |
Aadi Bioscience reports Q1 EPS (66c), consensus (71c). |
|
Financial report |
190 |
Aemetis reports Q1 EPS (54c), consensus (39c). |
|
Financial report |
170 |
Aeterna Zentaris provides update on AIM Biologicals development program. |
|
|
230 |
Affimed to present preclinical data on cytotoxic activity of AFM28. |
|
|
230 |
Affirm extends multi-year partnership with Shopify in U.S. |
|
|
157 |
Akouos reports Q1 EPS (78c), consensus (73c). |
|
Financial report |
167 |
Algonquin Power increases common dividend 6% to $0.1808 per share. |
|
|
173 |
Alimera notes positive predictive value of corticosteroids before Iluvien. |
|
|
330 |
Ameresco in supply pact with Powin for 2,500 MWh of BESS. |
|
|
241 |
Amprius Technologies to go public via merger with Kensington Capital. |
|
|
196 |
Applied DNA Sciences reports Q2 EPS (23c), consensus (33c). |
|
Financial report |
422 |
Aptevo Therapeutics reports Q1 EPS ($1.55) vs. ($1.64) last year. |
|
Financial report |
163 |
Aptinyx reports Q1 EPS (29c), consensus (30c). |
|
Financial report |
211 |
Apyx Medical reports Q1 EPS (17c), consensus (15c). |
|
Financial report |
190 |
Aravive reports Q1 EPS (62c), consensus (53c). |
|
|
154 |
Arcellx reports Q1 EPS ($1.56), consensus (64c). |
|
Financial report |
227 |
Asahi Kasei to start providing carbon footprint data for rubber, elastomers. |
|
|
216 |
Assembly Biosciences reports Q1 EPS (48c), consensus (47c). |
|
Financial report |
168 |
Athira Pharma Q1 EPS (56c) vs. (25c) last year. |
|
Financial report |
322 |
Athira Pharma urges holders to back its director nominees at May 19 AM. |
|
|
196 |
Aurora Cannabis raises expense savings target to C$150M-C$170M. |
|
|
161 |
Bausch + Lomb release survey findings on macular edema treatment. |
|
|
289 |
BD announces U.S. launch of infectious disease molecular diagnostics platform. |
|
|
227 |
Bio-Techne and Nonagen Bioscience enter supply agreement for bladder cancer test. |
|
|
165 |
Bioceres reports Q3 revenue $60.1M, consensus $44.74M. |
|
Financial report |
341 |
Biolase reports Q1 EPS (77c), consensus (68c). |
|
Financial report |
177 |
Bionano Genomics reports publication highlighting utility of OGM. |
|
|
291 |
BiondVax provides update on NanoAbs program at Biomed conference. |
|
Conference news |
235 |
BK Technologies reports Q1 EPS (23c) vs. (5c) last year. |
|
Financial report |
312 |
Blend Labs reports Q1 EPS (32c), consensus (19c). |
|
Financial report |
189 |
Blue Bird reports Q2 EPS (38c) vs. (36c) last year. |
|
Financial report |
184 |
Boxlight reports Q1 EPS (7c), consensus (6c). |
|
Financial report |
190 |
Bragg's Wild Streak strengthens game development collaboration with IGT. |
|
|
211 |
BRC Inc. reports Q1 EPS ($1.36), consensus (2c). |
|
Financial report |
222 |
Brickell Biotech reports Q1 EPS (8c), consensus (6c). |
|
Financial report |
217 |
BridgeBio announces license agreement with Bristol-Myers for BBP-398. |
|
|
199 |
Brilliant Earth reports Q1 adjusted EPS 5c, consensus 4c. |
|
Financial report |
209 |
Brookline bullish on Caribou after 'truly stunning' CB-010 data in r/r B-NHL. |
|
|
169 |
Cabaletta Bio reports Q1 EPS (45c), consensus (60c). |
|
Financial report |
195 |
Calix teams with Bark Technologies on mitigating 'cyberbullying'. |
|
|
271 |
Carbon Streaming announces first biochar carbon stream. |
|
|
351 |
Caribou Biosciences announces initial data for CB-010. |
|
|
307 |
Cascades reports Q1 adjusted EPS (C$0.15) vs. C$0.29 last year. |
|
Financial report |
464 |
Casi Pharmaceuticals reports Q1 EPS (6c), consensus (9c). |
|
Financial report |
188 |
Chemomab Therapeutics reports Q1 EPS (2c) vs. (1c) last year. |
|
Financial report |
255 |
ChromaDex backs FY22 revenue growth view 15%-20%, consensus $79.36M. |
|
|
152 |
Compass reports Q1 EPS (45c), consensus (48c). |
|
Financial report |
167 |
Constellation Energy reports Q1 EPS 32c, consensus 70c. |
|
Financial report |
206 |
CorMedix announces leadership updates, operational changes. |
|
|
193 |
Crescent Point Energy raises quarterly dividend by over 40% to 6.5c per share. |
|
|
255 |
Crescent Point Energy reports Q1 adjusted EPS 41c, consensus 25c. |
|
Financial report |
175 |
Crescent Point now expects to generate $1.2B-$1.4B of excess cash flow in 2022. |
|
|
240 |
Crexendo reports Q1 adjusted EPS 2c, consensus 1c. |
|
Financial report |
202 |
Crinetics reports Q1 EPS (73c), consensus (58c). |
|
Financial report |
166 |
Cullinan, Taiho Pharmaceutical to jointly develop CLN-081/TAS6417. |
|
|
236 |
CymaBay reports Q1 EPS (32c), consensus (31c). |
|
Financial report |
216 |
Cyxtera Technologies expands to India via partnership with Sify Technologies. |
|
|
198 |
D-Orbit successfully completes fifth ION satellite carrier mission. |
|
|
156 |
D-Wave announces availability of Advantage quantum computer. |
|
|
245 |
DarioHealth reports Q1 EPS (74c), consensus (96c). |
|
Financial report |
158 |
Day One Biopharmaceuticals reports Q1 EPS (48c), consensus (38c). |
|
Financial report |
176 |
Digital Realty contracts for 158MW of renewable energy in California and Georgia. |
|
|
156 |
Duolingo reports Q1 EPS (31c), consensus (57c). |
|
Financial report |
155 |
Dynatronics reports Q3 EPS (9c) vs. (0c) last year. |
|
Financial report |
179 |
Dynatronics sees 2022 revenue $44M-$45M. |
|
|
313 |
eMagin reports Q1 adjusted EPS (2c) vs (10c) last year. |
|
Financial report |
162 |
Energy Action:. |
|
|
214 |
Energy Vault increases scope of energy storage project with DG Fuels. |
|
|
215 |
ESS Inc. reports Q1 EPS (4c), consensus (13c). |
|
Financial report |
171 |
Evelo Biosciences reports Q1 EPS (56c), consensus (58c). |
|
Financial report |
190 |
Evelo Biosciences reports Q1 EPS (56c), consensus (58c). |
|
Financial report |
175 |
Flora Growth establishes on-the-ground presence in UK and EU. |
|
|
182 |
Flux Power reports Q3 EPS (23c), consensus (28c). |
|
Financial report |
249 |
FX update: haven demand is boosting the dollar and the yen. |
|
|
157 |
Global Blood Therapeutics announces data presentations on Sickle Cell Disease. |
|
|
503 |
Global Ship Lease announces participation in carbon capture initiative. |
|
|
255 |
Gracell to present clinical data on GC012F in RRMM and B-NHL at EHA2022. |
|
|
185 |
Graphite Bio reports Q1 EPS (48c), consensus (39c). |
|
Financial report |
171 |
Greenpro Capital, Cryptosx create crypto exchange in Malaysia. |
|
|
197 |
Idaho Strategic announces addition of Lemhi Pass REE project in Idaho. |
|
|
468 |
Imago BioSciences reports Q1 EPS (49c), consensus (43c). |
|
Financial report |
248 |
Ingevity publishes environmental product declaration for Evotherm WMA. |
|
|
200 |
iTeos Therapeutics reports Q1 EPS ($1.96)), consensus 79c. |
|
Financial report |
207 |
Jacobs/Morrison Energy Services JV secures National Grid projects. |
|
|
182 |
Jaguar Mining reports Q1 EPS (8c) vs. 8c last year. |
|
Financial report |
186 |
Jasper Therapeutics to initiate registrational studies in MDS and AML in 1Q23. |
|
|
234 |
Kinnate Biopharma reports Q1 EPS (61c), consensus (61c). |
|
Financial report |
184 |
Knight, Helsinn enter license agreement for Akynzeo, Aloxi. |
|
|
173 |
Lava Therapeutics announces IND clearance for LAVA-051. |
|
|
169 |
LianBio reports Q1 EPS (26c), consensus (30c). |
|
Financial report |
172 |
Lineage Cell Therapeutics reports Q1 EPS (4c), consensus (3c). |
|
Financial report |
245 |
MakerBot, Ultimaker enter business combination agreement. |
|
|
175 |
Matinas BioPharma reports Q1 adjusted EPS 0c, consensus 0c. |
|
Financial report |
157 |
MediWound announces results from US Phase 2 trial of EscharEx. |
|
|
346 |
MeiraGTx reports Q1 EPS (70c), consensus (52c). |
|
|
225 |
MIND C.T.I. reports Q1 EPS 7c vs 7c last year. |
|
Financial report |
202 |
Mindset Pharma progresses plans for trials of MSP-1014. |
|
|
175 |
Mogo reports Q1 adj. EBITDA loss of $5.5M vs. loss of $1.1M in year ago quarter. |
|
Financial report |
159 |
MoneyLion reports Q1 adj EBITDA loss $24.9M vs. loss of $1.2M in last year's. |
|
Financial report |
174 |
MoonLake Immunotherapeutics starts Phase 2 Nanobody Sonelokimab trial. |
|
|
167 |
MorphoSys to present new data on Pelabresib and Monjuvi at EHA and ASCO. |
|
|
191 |
Motus GI Holdings reports Q1 EPS (9c), consensus (11c). |
|
Financial report |
230 |
Muscle Maker reports Q1 EPS (7c) vs. (31c) last year. |
|
|
432 |
Mustang Bio reports Q1 EPS (20c) vs. (19c) last year. |
|
Financial report |
209 |
Mustang Bio says MB-106 trial selected for oral presentation at EHA2022. |
|
|
244 |
Mynaric, Airbus U.S. Space & Defense sign contract fo laser communication demo. |
|
|
203 |
NeuBase Therapeutics reports Q1 EPS (30c), consensus (23c). |
|
Financial report |
228 |
Newegg Commerce shares insights about Newegg Live. |
|
|
269 |
Neximmune reports Q1 EPS (66c), consensus (70c). |
|
Financial report |
222 |
NGM Biopharmaceuticals announces initiation of Phase 1/1b study of NGM438. |
|
|
155 |
Nice reports Q1 adjusted EPS $1.80, consensus $1.71. |
|
Financial report |
163 |
Nkarta reports Q1 EPS (79c), consensus (72c). |
|
Financial report |
165 |
Nuvalent reports Q1 EPS (36c), consensus (40c). |
|
Financial report |
172 |
Orbit International reports Q1 adjusted EPS 16c vs 54c last year. |
|
Financial report |
241 |
Pacira reports preliminary April net product sales for Exparel, iovera of $45.8M. |
|
Financial report |
263 |
Pear Therapeutics includes QuickMD in telehealth provider experience initiative. |
|
|
161 |
PepsiCo taps Billtrust's ACA solution for hard Mountain Dew distribution. |
|
|
185 |
Poseida Therapeutics reports Q1 EPS (93c), consensus (66c). |
|
Financial report |
186 |
Precision BioSciences announces grant of inducement awards under Nasdaq rule. |
|
|
168 |
Priority Technology to launch solution for construction payment challenges. |
|
Conference notes |
244 |
Protara Therapeutics presents results of retrospective analysis of OK-432. |
|
Clinical report |
301 |
PureCycle reports 215M pounds of polypropylene under LOI. |
|
|
204 |
PureCycle says purification facility in Ironton, Ohio remains on track. |
|
|
293 |
Quarterhill reports Q1 EPS C$0.44 vs. (C$0.04) last year. |
|
Financial report |
245 |
Quebecor reports Q1 adjusted EPS C$0.54 vs. C$0.52 last year. |
|
Financial report |
592 |
Realogy to rebrand as Anywhere Real Estate. |
|
|
176 |
Revitalist Lifestyle and Wellness reports April revenue C$480,000. |
|
Financial report |
300 |
Rockley Photonics announces $81.5M private placement. |
|
|
236 |
Sema4 Holdings reports Q1 EPS (31c), consensus (31c). |
|
Financial report |
246 |
Sigilon Therapeutics reports Q1 EPS (43c), consensus (33c). |
|
Financial report |
166 |
SilverSun Technologies reports Q1 EPS (1c) vs. 7c last year. |
|
Financial report |
412 |
Skye Bioscience signs arrangement agreement with Emerald Health Therapeutics. |
|
|
324 |
SkyWater in license pact with Xperi for hybrid bonding technology. |
|
|
151 |
Smith-Midland Corp continues to face macro challenges. |
|
|
154 |
Smith-Midland Corp reports Q1 EPS (2c) vs. 55c last year. |
|
Financial report |
391 |
Snap One raises FY22 revenue view $1.16B-$1.18B from $1.14B-$1.17B. |
|
|
293 |
Snap One reports Q1 EPS (3c), consensus 9c. |
|
Financial report |
194 |
STMicroelectronics targets FY25-FY27 revenue $20B+. |
|
|
188 |
Stratasys says MakerBot to merge with Ultimaker. |
|
|
253 |
Taboola reports Q1 EPS 8.5c, consensus 5c. |
|
Financial report |
169 |
TCR2 Therapeutics reports Q1 EPS (76c), consensus (74c). |
|
Financial report |
216 |
The 1k initial claims uptick to 203k. |
|
|
193 |
The April U.S. PPI gains. |
|
|
188 |
Theseus Pharmaceuticals reports Q1 EPS (27c), consensus (26c). |
|
Financial report |
177 |
Titan Medical reports cash, cash equivalents of $30.1M as of March 31. |
|
|
231 |
Treasury Action: bonds retain a strong risk off bid. |
|
|
171 |
Treasury Action: risk aversion has seen yields dive globally. |
|
|
236 |
Treasury Market Outlook. |
|
|
204 |
Treasury Market Summary:. |
|
|
215 |
Treasury's $ B 4- and 8-week bill offerings were weak. |
|
|
166 |
Treasury's $22 B 30-year bond auction was very well received. |
|
|
190 |
TUV SUD supports Microvast in sustainable battery production. |
|
|
197 |
Twin Vee PowerCats reports Q1 EPS (17c) vs. 3c last year. |
|
Financial report |
441 |
Tyson made 'baseless' claims to keep plants open during COVID, House says. |
|
|
154 |
Unicycive Therapeutics reports Q1 EPS (24c) vs (11c) last year. |
|
Financial report |
189 |
Utz Brands raises FY22 revenue growth view to 10%-13% from 7%-10%. |
|
|
337 |
Vallon Pharmaceuticals reports additional data from SEAL study of ADAIR. |
|
|
459 |
Ventyx Biosciences reports Q1 EPS (45c), consensus (52c). |
|
Financial report |
154 |
Veru reports Q2 EPS (18c), consensus (15c). |
|
Financial report |
206 |
Vigil Neuroscience on track to report VGL101 Phase 1 data in 2H. |
|
|
199 |
VYNE Therapeutics reports adjusted Q1 EPS (14c) vs (18c) last year. |
|
Financial report |
160 |
Wave Life Sciences reports Q1 EPS (62c), consensus (55c). |
|
Financial report |
203 |
WestRock publishes 2021 sustainability report. |
|
|
285 |
WM Technology launches payments in Ontario. |
|
|
211 |
Wolfe downgrades credit card issuers on 80% probability of recession. |
|
|
221 |
Xebec Adsorption reports Q1 EPS (C$0.12) vs. (C$0.07) last year. |
|
Financial report |
171 |
Zealand Pharma sees FY22 net operating expenses DKK $1B plus or minus 10%. |
|
|
209 |
Zevia reports Q1 EPS (30c), consensus (15c). |
|
Financial report |
174 |
Zoom Video enters agreement to acquire Solvvy. |
|
|
169 |